Keyphrases
Levodopa-carbidopa Intestinal Gel
100%
Late-onset Parkinson's Disease
100%
Cost-effectiveness Analysis
100%
Advanced Parkinson's Disease
50%
OFF Time
25%
Incremental Cost
25%
Parkinson Patients
25%
Cost-effectiveness
25%
Health Status
25%
Quality of Life Improvement
12%
Service Perspective
12%
Advanced PD
12%
Levodopa-responsive
12%
UK NHS
12%
Effective Treatment
12%
Treatment Options
12%
Personal Social Services
12%
Markov Model
12%
Quality-adjusted Life Years
12%
Cost Analysis
12%
Cost per QALY
12%
One-way Sensitivity Analysis
12%
Lifetime Analysis
12%
Availability Constraints
12%
Orphan Drugs
12%
Off-state
12%
Oral Medication
12%
Long-term Benefit
12%
Life-years Gained
12%
Incremental Cost-effectiveness Ratio
12%
Continuous Dopaminergic Stimulation
12%
Time-to-treatment
12%
Gel Treatment
12%
Treatment Initiation
12%
Data Availability
12%
Motor Fluctuations
12%
Medicine and Dentistry
Late Stage Parkinson's Disease
100%
Cost-Effectiveness Analysis
100%
Carbidopa/Levodopa
100%
Health Care Cost
50%
Quality Adjusted Life Year
50%
Parkinson's Disease
50%
Lifespan
25%
Health Status
25%
Quality of Life
12%
Orphan Drug
12%
Cost Benefit Analysis
12%
Drug Therapy
12%
Levodopa
12%
Pharmacology, Toxicology and Pharmaceutical Science
Parkinson's Disease
100%
Carbidopa Plus Levodopa
100%
Health Status
25%
Orphan Drug
12%
Dopamine Receptor Stimulating Agent
12%
Levodopa
12%